Positives

• A lupus patient on the type-I interferon receptor blocker reported noticeable rash and joint improvement within weeks, with full benefit emerging over three to six months and a successful steroid taper Lupus Foundation.
  
  
• In four-year extension data, more patients on the IFN-1 blocker (30%) reached remission compared with standard therapy alone (18%), which several users tied to durable energy and concentration gains Drugs.com.
  
  

Negatives

• Patients reported nasopharyngitis, bronchitis, and a noticeably higher rate of shingles reactivation, with some requiring antiviral prophylaxis Drugs.com.
  
  
• A user described an infusion-related reaction with chills and flushing that required slowing the rate and pre-medication for subsequent visits FDA.
  
  

Hurdles & Side Effects

• A patient with an interferon-signature Long COVID phenotype reported that no rheumatologist would prescribe the drug without a formal SLE diagnosis even when her IFN-stimulated gene panel was elevated Drugs.com.
  
  
• Users described monthly intravenous infusions as a major scheduling burden Drugs.com.